1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | QGP 1; QGP1 |
| Species | Human |
| Cat.No | ABC-TC0918 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
QGP-1 is a neuroendocrine tumor cell line of pancreatic origin and can produce carcinoembryonic antigen (CEA). It originates from the neuroendocrine system in the pancreas, as confirmed by the expression of the neuronal marker, synaptophysin. The expression of transcription factors involving neuroendocrine cell differentiation in the pancreas was observed in QGP-1 cells. 
Moreover, QGP-1 exhibited elevated gene expression levels related to immature or non-functional β/δ-cells genes, or pancreatic endocrine progenitors. QGP-1 is identified as G3 carcinomas by a Ki-67 (nuclear proliferation factor) labeling index of 82.6%±1.0%. When it was established in 1980, the doubling time of QGP-1 was about 84 hours (3.5 days), but this time was detected to be shorter, 38 hours, in 2018. With the use of these years, QGP-1 might become more malignant in culture. QGP-1 has the aberrant chromosome with a ploidy of 4.
Why choose QGP-1 from AcceGen?
AcceGen provides TE671 with numerous beneficial characteristics. We maintain strict sterility standards, ensuring the absence of bacterial, fungal, and mycoplasma contamination. Our exceptional cryopreservation techniques guarantee high cell viability, resulting in reliable experimental outcomes.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Si, Y., Kim, S., Guenter, R., Ou, J., Lu, Y., Chen, K., Zhang, J., Whitt, J., Carter, A.M., Bibb, J.A. and Jaskula-Sztul, R., 2019. Anti-SSTR2 Antibody-Drug Conjugate for Neuroendocrine Cancer Therapy. bioRxiv, p.688184.
Si, Y., Guan, J., Xu, Y., Chen, K., Kim, S., Zhou, L., Jaskula-Sztul, R. and Liu, X.M., 2020. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics, 12(11), p.1079.
Herring, B., Jang, S., Whitt, J., Goliwas, K., Aburjania, Z., Dudeja, V., Ren, B., Berry, J., Bibb, J., Frost, A. and Chen, H., 2021. Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates. Frontiers in endocrinology, 12.
FOR RESEARCH USE ONLY
Panceras neuroendocrine tumors (panNET) are relatively rare pancreatic neoplasms, with an incidence of 0.43 per 100 000, and their clinical options are limited. However, the rates have increased rapidly in recent years, emphasizing the urgency to find novel therapies for panNET. QGP-1 can be useful as an in vitro model or in establishing a in vivo model for the drug development of neuroendocrine tumors (NET). QGP-1 is also a model of human enterochromaffin (EC) cells used to investigate the transient receptor potential ankyrin1 channel (TRPA1) due to a high expression of TRPA1 and EC cell marker genes.
